Skip to Content

Healthier Frankenfoods?

When Swiss scientists reported earlier this year a genetically engineered strain of rice that produces beta-carotene, a source of vitamin A, it was hailed as a breakthrough that could help save the lives of an estimated 1 million to 2 million children each year in the developing world. It also came as a much-needed shot in the arm for the beleaguered agricultural biotech industry.

The growing opposition to biotech foods around the world is threatening the future of the technology. And a number of industry executives now acknowledge that the problem with first-generation products-for example, Monsanto’s herbicide-resistant soybeans and insect-tolerant corn-is that while they may save farmers money and cut down on chemical use, they lack a visible payoff for the average shopper. “There may be risks with no benefit. So the consumer says ‘why should I put up with it?’,” says David Wheat, an industry analyst at the Bowditch Group in Boston, Mass.

While nutrition in developing countries has never topped the biotech industry’s to-do list, companies hope their next generation of products gets a warmer reception. That generation will include many crops with genetically engineered “output traits” that improve a plant’s taste, size or nutritional value. One of the first to reach market is a DuPont soybean engineered to produce a frying oil without trans-fatty acids, a current villain in public health circles. “The consumer won’t know quite what kind of oil was used to make the donut, but the consumer can read a label that says zero trans-fats and that’s what matters,” says Wheat. According to Virginia Tech’s Information Systems for Biotechnology, about 16 percent of the 800 biotech plants currently in field testing are aimed at improving such output traits.

Keep Reading

Most Popular

VR is as good as psychedelics at helping people reach transcendence

On key metrics, a VR experience elicited a response indistinguishable from subjects who took medium doses of LSD or magic mushrooms.

This startup wants to copy you into an embryo for organ harvesting

With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.

This nanoparticle could be the key to a universal covid vaccine

Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.